DEF: BillionToOne 2026 Annual Meeting Proxy Statement

BillionToOne, Inc. has issued its 2026 proxy statement detailing the agenda for its upcoming annual meeting of stockholders to be held on June 10, 2026.

Summary

• The 2026 Annual Meeting of Stockholders will be held virtually on June 10, 2026, at 9:00 a.m. PDT.
• Stockholders of record as of April 17, 2026, are entitled to vote.
• Proposal 1: Election of two Class I directors, Oguzhan Atay and Akshay Rai, to serve until the 2029 annual meeting.
• Proposal 2: Ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
• The company is an emerging growth company under the JOBS Act.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a standard, routine administrative filing for a recently public company, reflecting normal corporate governance and compliance activities.

Positives

• Successful transition to public company status in 2025.
• Strong alignment of executive interests with shareholders through significant equity ownership.
• Established robust corporate governance structures, including an Audit Committee and Compensation Committee.
• Successful recruitment of experienced executive leadership, including a new Chief Administrative Officer in 2025.

Negatives

• Audit fees increased significantly from $875,000 in 2024 to $3,075,000 in 2025, reflecting the costs associated with becoming a public company.
• The company has a dual-class stock structure where Class B shares carry 15 votes per share, concentrating voting power among founders.
• The classified board structure may delay or prevent changes in control or management.

Risks

• The classified board structure may have the effect of delaying or preventing changes in control or management.
• The company is an emerging growth company and may rely on exemptions from certain disclosure requirements.
• The company faces intense competition for talent in the biotechnology and diagnostics industry.

Future Outlook

The company intends to continue its mission of transforming healthcare by redefining molecular diagnostics and expects to maintain its executive compensation philosophy of overweighting equity relative to cash to align with long-term shareholder value.

Management Comments

• We believe holding our Annual Meeting online will facilitate greater stockholder attendance while still providing comparable rights and opportunities to participate.
• We believe that executives who are significant owners of BillionToOne stock are best positioned to make decisions that create long-term value.

Industry Context

StockSavvy.ai notes that BillionToOne is following standard post-IPO governance practices, including the establishment of board committees and the adoption of clawback policies, consistent with other high-growth biotechnology firms.

Comparison to Industry Standards

• The company's use of a dual-class share structure is common among founder-led technology and biotech companies.
• The board composition includes members with significant venture capital and public company experience, aligning with industry norms for recently public firms.
• The executive compensation structure, heavily weighted toward equity, is standard for the biotechnology sector to ensure retention of key talent.

Management Changes

Corporate Governance

Legal Proceedings

• None disclosed.

Related Party Transactions

• Exchange agreements with CEO Oguzhan Atay and CTO David Tsao to convert Class A to Class B shares.
• Participation of directors and officers in the IPO directed share program.
• Indemnification agreements with directors and executive officers.

Stakeholder Impact

• Shareholders are requested to vote on director elections and auditor ratification.
• Employees and executives are subject to updated compensation and clawback policies.

Next Steps

• Hold the 2026 Annual Meeting of Stockholders on June 10, 2026.
• Tabulate and announce voting results on a Form 8-K within four business days of the meeting.

Key Dates

Keywords

BillionToOne, Proxy Statement, Annual Meeting, Corporate Governance, Executive Compensation, Molecular Diagnostics, BLLN